GAB1 Antibody

What is GAB1 and what are its primary functions in cellular signaling?

GAB1 (GRB2-associated-binding protein 1) is a critical docking protein encoded by the GAB1 gene that serves as a central mediator in multiple signaling pathways. It functions as part of the IRS1-like multisubstrate docking protein family that transduces signals from various tyrosine kinases, including Met, FGFR1, and EGFR . GAB1 plays essential roles in cellular growth responses, transformation processes, apoptosis regulation, and inflammatory responses .

In terms of molecular function, GAB1 contains a highly conserved pleckstrin homology (PH) domain (amino acids 14-99) at its amino-terminal end that interacts with phosphatidylinositol 3,4,5-triphosphate (PIP3) at the plasma membrane. It also features a central proline-rich domain that interacts with proteins containing SRC homology 3 (SH3) domains, along with 47 predicted phosphorylation sites on serine/threonine residues and 16 potential phosphotyrosine sites that recruit proteins with SRC homology 2 (SH2) domains .

Unlike other family members, GAB1 contains a unique MET-binding domain (MBD) (amino acids 450-532) within the proline-rich domain, enabling direct association with the MET receptor . This structural feature allows GAB1 to serve as a critical hub in signal transduction networks.

How does GAB1 contribute to major downstream signaling pathways?

Upon receiving various stimuli, GAB1 translocates from the cytoplasm to the membrane where it undergoes phosphorylation by different kinases . This phosphorylation creates binding sites for various SH2 domain-containing proteins, including:

• SHP2 phosphatase - leading to MAPK pathway activation

• PI3K's p85 subunit - activating the PI3K/AKT pathway

• Phospholipase C γ (PLCγ) - binding at tyrosine residues Y307, Y373, and Y407

• CRK and CRK-like (CRKL) adaptor proteins

• P21-activated kinase 4 (PAK4)

• Members of the partitioning defective (PAR) complex

GAB1 is crucial for EGF-induced activation of the PI3K/AKT signaling pathway through its association with the p85 subunit of PI3K . Additionally, GAB1 overexpression potentiates EGF-induced activation of the MAPK pathway, while its downregulation reduces both PI3K/AKT and MAPK pathway-mediated signaling and shortens signaling duration after EGF stimulation .

What tissue expression patterns are observed for GAB1?

GAB1 exhibits wide expression across multiple tissue types . Research using GAB1 antibodies has demonstrated important developmental roles, as GAB1-deficient embryos die in utero with developmental abnormalities in several organs and tissues including:

• Heart

• Placenta

• Liver

• Skin

• Limb

• Diaphragm myocytes

For immunohistochemical detection, tissue controls that typically express detectable levels of GAB1 include breast, prostate, testis, tonsil, stomach, and transitional cell carcinoma samples . This widespread expression pattern reflects GAB1's fundamental role in basic cellular processes.

What are the most validated applications for GAB1 antibodies in research?

GAB1 antibodies are versatile tools employed across multiple experimental techniques. Based on the research literature, the most common applications include:

Over 130 citations in the scientific literature describe the use of GAB1 antibodies in research, with Western blotting being the most frequently employed technique . When conducting Western blot analysis, GAB1 antibodies typically detect a band of approximately 102 kDa in cell lysates such as those from HepG2 cells .

How can phospho-specific GAB1 antibodies be used to investigate signaling dynamics?

Phospho-specific GAB1 antibodies allow researchers to track the activation status of GAB1 in response to various stimuli. Several well-characterized phospho-specific antibodies target key regulatory sites:

• Phospho-Gab1 (Tyr307) antibodies - This phosphorylation site creates a binding interface for PLCγ

• Phospho-Gab1 (Tyr627) antibodies - Phosphorylation at this position leads to SHP2 recruitment and subsequent MAPK signaling activation

• Phospho-Gab1 (Tyr659) antibodies - Another key regulatory phosphorylation site

When designing time-course experiments to study GAB1 activation dynamics, researchers should:

• Include appropriate positive controls (e.g., EGF or HGF stimulated cells)

• Use total GAB1 antibodies in parallel to normalize phospho-signals

• Consider using phosphatase inhibitors during sample preparation to preserve phosphorylation status

• Validate antibody specificity using phosphatase treatments

These phospho-specific antibodies are particularly valuable for investigating how different upstream stimuli may preferentially activate distinct downstream pathways through GAB1 phosphorylation patterns.

What role does GAB1 play in cancer research and how can GAB1 antibodies contribute to oncology studies?

GAB1 has emerged as an important focus in cancer research due to its role in key cancer-related processes including:

• Proliferation and cell growth - GAB1 significantly influences cellular transformation by modulating proliferation pathways

• Evasion of apoptosis - GAB1 signaling affects cell survival mechanisms

• Metastasis - The GAB1-CRK interaction enhances cell scattering and invasive capacity in cancer models

• Angiogenesis - GAB1 contributes to processes that support tumor vascularization

GAB1 antibodies can be utilized in cancer research to:

• Assess GAB1 expression levels, which correlate with poor prognosis in gliomas, hepatocellular carcinoma, and ovarian cancer

• Investigate GAB1's role in therapy resistance, as it modulates sensitivity to anticancer treatments

• Study GAB1 mutations and fusions such as the ABL-GAB1 fusion identified in perineurioma, angiofibroma, and solitary fibrous tumors

• Monitor GAB1-mediated signaling in response to targeted therapy (e.g., EGFR inhibitors)

Additionally, high GAB1 expression has been associated with breast cancer metastasis through mechanisms involving dissociation of the polarity-associated partitioning defective (PAR) complex and promotion of epithelial-to-mesenchymal transition .

How can researchers differentiate between GAB1 isoforms in experimental systems?

The human GAB1 gene encodes up to two different isoforms , which presents challenges for researchers attempting to distinguish between these variants. Methodological approaches to differentiate GAB1 isoforms include:

• Isoform-specific antibodies: Select antibodies targeting unique epitopes in specific isoforms

• RT-PCR with isoform-specific primers: Design primers spanning exon junctions unique to each isoform

• Western blot analysis with gradient gels: Use high-percentage gradient gels to resolve small molecular weight differences between isoforms

• Mass spectrometry: For definitive identification of specific isoforms and their post-translational modifications

When working with commercial antibodies, researchers should carefully review the immunogen information. For instance, some antibodies are raised against recombinant proteins covering amino acids 243-694 of human GAB1 , which may not detect all isoforms equally.

What are the optimal sample preparation methods for preserving GAB1 phosphorylation status?

Preserving GAB1 phosphorylation status is critical for accurately assessing its activation in experimental systems. The following protocol recommendations can help maintain phosphorylation integrity:

• Rapid sample collection and processing:

  • Stimulate cells for appropriate time periods (e.g., 5-30 minutes for acute responses)

  • Quickly aspirate media and wash once with ice-cold PBS

  • Add ice-cold lysis buffer directly to plates/flasks

• Lysis buffer composition:

  • Base buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40 or Triton X-100

  • Phosphatase inhibitors: 10 mM NaF, 1 mM Na3VO4, 10 mM β-glycerophosphate, 1 mM EDTA

  • Protease inhibitors: Complete protease inhibitor cocktail

• Sample handling:

  • Maintain samples at 4°C throughout processing

  • Avoid repeated freeze-thaw cycles

  • For long-term storage, aliquot samples and store at -80°C

• Western blot considerations:

  • Include phosphatase-treated controls to confirm specificity

  • Use freshly prepared SDS-PAGE buffers

  • Consider adding phosphatase inhibitors to transfer buffers

These precautions are particularly important when studying transient phosphorylation events, such as those occurring after growth factor stimulation of cells.

How can multiplex analysis be used to study GAB1 interactions with binding partners?

GAB1 serves as a crucial hub in signaling networks by interacting with multiple proteins. Advanced techniques for studying these interactions include:

• Co-immunoprecipitation with GAB1 antibodies:

  • Use gentle lysis conditions to preserve protein complexes

  • Include appropriate controls (IgG control, lysate without antibody)

  • Consider crosslinking to stabilize transient interactions

• Proximity ligation assay (PLA):

  • Enables visualization of protein interactions in situ

  • Particularly valuable for studying context-dependent interactions

  • Can be quantified to assess interaction dynamics

• Multiplexed immunofluorescence:

  • Allows simultaneous detection of GAB1 and its binding partners

  • Can be combined with phospho-specific antibodies to correlate activation states

• Mass spectrometry-based interactomics:

  • Immunoprecipitate GAB1 and identify interacting proteins

  • Compare interaction profiles under different stimulation conditions

  • Quantify changes in interaction strength

These approaches can reveal how GAB1 differentially interacts with proteins like SHP2, p85, CRK, CRKL, PAK4, and members of the PAR complex under various physiological and pathological conditions .

What are common challenges with GAB1 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with GAB1 antibodies:

• Background signal issues:

  • Optimize blocking conditions (test BSA vs. milk)

  • Try alternative antibody dilutions (typically 1:1,000 for Western blot)

  • Include additional washing steps with higher detergent concentrations

  • Consider using alternative secondary antibodies

• Specificity concerns:

  • Validate with positive and negative controls

  • Compare multiple antibodies targeting different epitopes

  • Include GAB1 knockdown/knockout samples when possible

  • Verify molecular weight (approximately 102 kDa in Western blots)

• Signal variability:

  • Standardize lysate preparation to ensure consistent protein levels

  • Include loading controls for normalization

  • Consider the impact of cell confluence and passage number

• Cross-reactivity with related proteins:

  • GAB1 shares homology with other GAB family members

  • Validate specificity with recombinant proteins or overexpression systems

For concentrated antibody preparations, manufacturers recommend centrifuging prior to use to ensure recovery of all product .

What are the best practices for validating GAB1 antibody specificity in different applications?

Thorough validation of GAB1 antibodies is essential for obtaining reliable results. The following application-specific validation approaches are recommended:

For Western Blotting:

• Compare observed molecular weight (~102 kDa) with expected size

• Include positive control samples (e.g., HepG2 cell lysates)

• Run a negative control (GAB1 knockdown/knockout if available)

• Perform peptide competition assays with the immunizing peptide

• Test multiple antibody dilutions to determine optimal signal-to-noise ratio

For Immunohistochemistry:

• Use recommended positive control tissues (breast, prostate, testis, tonsil, stomach)

• Include negative control tissues known to lack GAB1 expression

• Perform parallel staining with isotype control antibody

• Compare staining patterns (cytoplasmic, membranous, nuclear) with published reports

• Validate findings with a second antibody targeting a different epitope

For Immunofluorescence:

• Compare subcellular localization with published data

• Perform co-localization studies with organelle markers

• Include stimulation conditions known to alter GAB1 localization

Documentation of these validation steps should be included in research publications to ensure reproducibility and reliability of findings.

How might GAB1 research contribute to novel cancer therapeutics?

GAB1's central role in cancer-promoting signaling pathways positions it as a promising target for therapeutic intervention. Future research directions include:

• Targeting GAB1-mediated therapy resistance:

  • GAB1 modulates resistance/sensitivity to antitumor therapies, making it a potential target for overcoming treatment resistance

  • Development of compounds disrupting specific GAB1 interactions could sensitize cancer cells to existing therapies

• Exploiting GAB1 mutations and fusions:

  • ABL-GAB1 fusions identified in perineurioma and other tumors represent potential therapeutic targets

  • EIF4G2-GAB1 fusions found in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors suggest roles in therapy adaptation

• Leveraging GAB1 as a prognostic biomarker:

  • High GAB1 expression correlates with poor prognosis in multiple cancer types including gliomas, hepatocellular carcinoma, and ovarian cancer

  • GAB1 antibodies could be developed for diagnostic applications to identify patients with potentially aggressive disease

• Investigating GAB1 polymorphisms:

  • Genetic polymorphisms in GAB1 increase susceptibility to certain cancers including cholangiocarcinoma, meningiomas, and lung cancer

  • Understanding how these variants affect GAB1 function could guide personalized treatment approaches

These research directions highlight the importance of continued investigation into GAB1 biology and the development of high-quality, specific antibodies for both research and potential clinical applications.

What methodological advances are needed to better understand GAB1 signaling complexity?

Despite significant progress in GAB1 research, several methodological challenges remain:

• Temporal and spatial dynamics:

  • Development of biosensors to monitor GAB1 activation in real-time

  • Advanced imaging techniques to track GAB1 translocation and complex formation

  • Single-cell analysis to understand heterogeneity in GAB1 signaling

• Isoform-specific functions:

  • Creation of isoform-selective antibodies and genetic models

  • Investigation of isoform-specific interactomes

  • Understanding differential regulation of GAB1 isoforms in various tissues

• Phosphorylation networks:

  • Comprehensive mapping of the 47 potential serine/threonine phosphorylation sites and 16 tyrosine phosphorylation sites

  • Development of additional phospho-specific antibodies

  • Understanding the temporal sequence of phosphorylation events

• Structural biology approaches:

  • Determination of full-length GAB1 structure

  • Structural characterization of GAB1 in complex with various binding partners

  • Rational design of inhibitors targeting specific GAB1 interactions

Advancing these methodologies will provide deeper insights into GAB1's diverse functions and potentially reveal new therapeutic opportunities across multiple disease contexts.